ITMCTR2200005560已完成1 期
A randomized, double-blind and double-dummy controlled trail of Hewei Jiangni Decoction in the treatment of nonerosive gastroesophageal reflux disease(cold and heat mixed syndrome)
Dongfang Hospital of Beijing University of Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 65（—）
- 性别
- All
入选标准
- •(1) patients who met the diagnostic criteria of Western medicine; (2) aged 18-65 years; (3) not receiving acid-inhibitory drugs or gastric mucosal protective agents within 2 weeks; (4) exclude other gastrointestinal diseases by gastroscopy to confirm NERD; (5) voluntarily participated in this study, written informed consent.
排除标准
- •(1) patients with reflux esophagitis, reflux hypersensitivity and Barrett's esophagus; (2) patients with a history of upper gastrointestinal bleeding or surgery, esophageal stenosis, esophageal and gastric tumors, and other organic lesions; (3) patients with cardiovascular and cerebrovascular diseases, liver, kidney and hematopoietic system and other serious primary diseases; (4) lactating and pregnant women; (5) patients with a history of mental or neurological disorders or those who are difficult to complete; (6) patients currently participating in other clinical trials.
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, double-dummy, two-way cross-overstudy evaluating systemic bioavailability and airway clearance ofSymbicort® Turbuhaler® 320/9µg/inhalation versus Seretide™ Diskus™50/500µg/inhalation after single inhalations in patients with ChronicObstructive Pulmonary Disease (COPD) and healthy volunteers - Airway clearanceThis is a Clinical Pharmacology study to be conducted in one patient group with severe COPD and one group of healthy volunteers.MedDRA version: 14.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2006-002412-10-DEAstraZeneca AB54
已完成
2 期
A clinical trial to study the evaluate the effective dose of Euphorbia prostrata in patients of pilesCTRI/2009/091/001020Panacea Biotec Ltd100
进行中（未招募）
不适用
A double-blind, double-dummy, prospective, randomized multiple-site study of oral Finafloxacin 300 mg b.i.d. versus oral Ciprofloxacin 250 mg b.i.d. in patients with lower uncomplicated UTI (uUTI) with a treatment duration of 3 days. - FLUTower uncomplicated Urinary Tract InfectionMedDRA version: 9.1Level: LLTClassification code 10046571Term: Urinary tract infectionEUCTR2007-007742-35-DEMerLion Pharmaceuticals GmbH48
进行中（未招募）
不适用
A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF) - ASSURE-AFthe prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (AF)MedDRA version: 9.1Level: LLTClassification code 10003658Term: Atrial fibrillationEUCTR2008-003698-42-DKAstraZeneca AB14,600
进行中（未招募）
不适用
A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF) - ASSURE-AFEUCTR2008-003698-42-BGAstraZeneca AB14,600